Fluorenone Compound DPOFA Renal Uric Acid Excretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for gout, primarily relying on xanthine oxidase inhibitors, are inadequate in managing elevated uric acid levels and reducing flare frequency, as they focus on uric acid production rather than renal excretion, leaving a significant unmet clinical need for effective urate-lowering therapy.
Innovation Solution
Administration of the fluorenone compound DPOFA or its ester/salt, which increases renal clearance of uric acid, reducing blood levels and preventing its reabsorption, thereby treating and preventing gout by enhancing uric acid excretion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If xanthine oxidase inhibitors are used to treat gout, then uric acid production is reduced, but renal excretion of uric acid remains insufficient leading to continued hyperuricemia
Solution Approach 1:
The invention segments the uric acid management approach into two distinct mechanisms: (1) reducing uric acid production via xanthine oxidase inhibition, and (2) enhancing renal excretion of uric acid. By adding the fluorenone compound that specifically targets renal excretion, the treatment addresses both pathways separately, overcoming the limitation of production-inhibition-only therapies
Solution Approach 2:
The invention merges two complementary mechanisms into a single therapeutic strategy: combining xanthine oxidase inhibition (reducing production) with fluorenone compound administration (enhancing renal excretion). This combined approach creates a more effective urate-lowering therapy that addresses both production and elimination pathways simultaneously
2Quantity of substance
If existing urate-lowering therapies are administered, then some reduction in uric acid occurs, but flare frequency remains high indicating inadequate treatment
Solution Approach 1:
The invention changes the therapeutic parameter from solely production inhibition to include enhanced renal excretion. By introducing the fluorenone compound that modifies the excretion parameter, the treatment achieves more effective uric acid lowering and consequently reduces flare frequency more substantially than production-inhibition therapies alone
3Quantity of substance
If renal secretion of uric acid is targeted for treatment, then excretion should increase, but no approved treatments currently exist for this mechanism
Solution Approach 1:
The fluorenone compound acts as an intermediary substance that mediates between the kidney's natural uric acid handling mechanisms and the therapeutic goal of increased excretion. It facilitates enhanced renal secretion without requiring existing approved treatments, thereby making this previously unavailable mechanism clinically accessible
Data Source
AI summary
The present invention provides a method for treating or preventing gout in a subject afflicted therewith comprising administering a compound presented or an ester or salt thereof, so as to thereby treat or prevent the gout in the subject.